期刊文献+

阿奇霉素治疗社区获得性肺炎的临床观察和费用分析

Clinical observation of azithromycin in community acquired pneumonia and its cost analysis
下载PDF
导出
摘要 目的:探讨阿奇霉素治疗社区获得性肺炎疗效并评价费用。方法:以2005~2006年在我校门诊部就诊患肺炎的学生118例为研究对象,随机分为试验组和对照组,试验组70例,用阿奇霉素治疗,对照组48例,用氧氟沙星治疗。两组患者的年龄、性别、病情差异无显著性(P>0.05)。结果:阿奇霉素治疗组治疗总有效率83%,氧氟沙星治疗组治疗总有效率62.5%。结论:采用阿奇霉素治疗社区获得性肺炎疗效好,费用低。 Objective:To study the effect of azithromycin in the treatment of community acquired pneumonia and evaluate its cost. Methods: 118 patients with community acquired pneumonia in out-patient department of Neijiang medical school were randomly divided into treatment group (n=70) and control group (n=48),and treated with azithromycin or ofloxacin,without statistical difference in age,sex and state of illness between two groups (P〉0.05). Results:The effective rate of azithromycin in the treatment group was 83% ,while the effective rate of ofloxacin in the control group was 62.5%. Conclusion :The effect of azithromycin in the treatment of community acquired pneumonia is fairly good, and its cost is relatively low.
作者 陈林果
机构地区 内江医科学校
出处 《现代医药卫生》 2008年第9期1299-1301,共3页 Journal of Modern Medicine & Health
关键词 社区获得性肺炎 阿奇霉素 氧氟沙星 Community acquired pneumonia Azithromycin Ofloxacin
  • 相关文献

参考文献4

二级参考文献20

  • 1Zhanel GG, Dueck M, Hoban DJ, et al. Review of maerolides and ketolides: focus on respiratory tract infections. Drugs,2001,61:443-498.
  • 2Rodvold KA, Gotfried MH, Danziger LH, et al. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob Agents Chemother, 1997,41 :1399-1402.
  • 3Patel KB, Xuan D, Tessier PR, et al. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob Agents Chemother, 1996,40:2375-2379.
  • 4Hoffman HL, Klepser ME, Ernst EJ, et al. Influence of macrolide susceptibility on eftlcacies of clarithromycin and azithromycin against Streptococcus pneumoniae in a murine lung infection model.Antimicrob Agents Chemother,2003 ,47 :739-746.
  • 5Tessier PR, Kim MK, Zhou W, et al. Pharmacodynamic assessment of clarithromycin in a murlne model of pneumococcal pneumonia.Antimicrob Agents Chemother,2002,46 : 1425-1434.
  • 6Lonks JR, Garau J, Gomez L, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromyein-resistant Streptococcus pneumoniae. Clin Infect Dis.2002.35:556-564.
  • 7Van Kerkhoven D, Peetermans WE, Verbist L, et al. Breakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral beta-lactams. J Antimicrob Chemother,2003,51:691-696.
  • 8Ewig S, Ruiz M, Tortes A, et al. Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae. Am J Respir Crit Care Med, 1999,159 : 1835-1842.
  • 9Waterer GW, Wunderink RG, Jones CB. Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy. Chest,2000,118 : 1839-1840.
  • 10Doern GV, Heilmann KP, Huynh HK,et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother, 2001,45: 1721-1729.

共引文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部